메뉴 건너뛰기




Volumn 33, Issue 4, 2011, Pages 425-442

Emerging antiplatelet therapies in percutaneous coronary intervention: A focus on prasugrel

Author keywords

ACS; Antiplatelet; Clopidogrel; PCI; Prasugrel; Thienopyridine

Indexed keywords

AMFEBUTAMONE; ANTITHROMBOCYTIC AGENT; CIMETIDINE; CLOPIDOGREL; ESOMEPRAZOLE; ETRAVIRINE; FELBAMATE; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; KETOCONAZOLE; OMEPRAZOLE; PRASUGREL; RIFAMPICIN; VORICONAZOLE;

EID: 79957647599     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.04.007     Document Type: Review
Times cited : (8)

References (69)
  • 1
    • 29344457180 scopus 로고    scopus 로고
    • ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
    • Smith S.C., Feldman T.E., Hirshfeld J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006, 47:e1-e121.
    • (2006) J Am Coll Cardiol , vol.47
    • Smith, S.C.1    Feldman, T.E.2    Hirshfeld, J.W.3
  • 2
    • 0035912690 scopus 로고    scopus 로고
    • ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions
    • Smith S.C., Dove J.T., Jacobs A.K., et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001, 103:3019-3041.
    • (2001) Circulation , vol.103 , pp. 3019-3041
    • Smith, S.C.1    Dove, J.T.2    Jacobs, A.K.3
  • 4
    • 0034622539 scopus 로고    scopus 로고
    • Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
    • Bertrand M.E., Rupprecht H.J., Urban P., et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000, 102:624-629.
    • (2000) Circulation , vol.102 , pp. 624-629
    • Bertrand, M.E.1    Rupprecht, H.J.2    Urban, P.3
  • 5
    • 70450199115 scopus 로고    scopus 로고
    • 2009 Focused Updates: ACC/AHA Guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guide
    • Kushner F.G., Hand M., Smith S.C., et al. 2009 Focused Updates: ACC/AHA Guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009, 54:2205-2241.
    • (2009) J Am Coll Cardiol , vol.54 , pp. 2205-2241
    • Kushner, F.G.1    Hand, M.2    Smith, S.C.3
  • 6
    • 38049183243 scopus 로고    scopus 로고
    • 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • Antman E.M., Hand M., Armstrong P.W., et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008, 117:296-329.
    • (2008) Circulation , vol.117 , pp. 296-329
    • Antman, E.M.1    Hand, M.2    Armstrong, P.W.3
  • 7
    • 38049169354 scopus 로고    scopus 로고
    • 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • King S.B., Smith S.C., Hirshfeld J.W., et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008, 117:261-295.
    • (2008) Circulation , vol.117 , pp. 261-295
    • King, S.B.1    Smith, S.C.2    Hirshfeld, J.W.3
  • 8
    • 33646732608 scopus 로고    scopus 로고
    • Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
    • Jernberg T., Payne C.D., Winters K.J., et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006, 27:1166-1173.
    • (2006) Eur Heart J , vol.27 , pp. 1166-1173
    • Jernberg, T.1    Payne, C.D.2    Winters, K.J.3
  • 9
    • 58749094444 scopus 로고    scopus 로고
    • Cytochrome p-450 polymorphisms and response to clopidogrel
    • Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
    • (2009) N Engl J Med , vol.360 , pp. 354-362
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 10
    • 77953911457 scopus 로고    scopus 로고
    • Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
    • Working Group on High On-Treatment Platelet Reactivity
    • Bonello L., Tantry U.S., Marcucci R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56:919-933. Working Group on High On-Treatment Platelet Reactivity.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 919-933
    • Bonello, L.1    Tantry, U.S.2    Marcucci, R.3
  • 11
    • 36148983750 scopus 로고    scopus 로고
    • Prasugrel versus clopidogrel in patients with acute coronary syndromes
    • Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
    • (2007) N Engl J Med , vol.357 , pp. 2001-2015
    • Wiviott, S.D.1    Braunwald, E.2    McCabe, C.H.3
  • 12
    • 33748680917 scopus 로고    scopus 로고
    • Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)
    • TRITON-TIMI 38 Investigators
    • Wiviott S.D., Antman E.M., Gibson C.M., et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006, 152:627-635. TRITON-TIMI 38 Investigators.
    • (2006) Am Heart J , vol.152 , pp. 627-635
    • Wiviott, S.D.1    Antman, E.M.2    Gibson, C.M.3
  • 13
    • 34249657466 scopus 로고    scopus 로고
    • Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians
    • Grines C.L., Bonow R.O., Casey D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc 2007, 138:652-655.
    • (2007) J Am Dent Assoc , vol.138 , pp. 652-655
    • Grines, C.L.1    Bonow, R.O.2    Casey, D.E.3
  • 14
    • 19644372173 scopus 로고    scopus 로고
    • Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention
    • Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005, 111:2560-2564.
    • (2005) Circulation , vol.111 , pp. 2560-2564
    • Hochholzer, W.1    Trenk, D.2    Frundi, D.3
  • 15
    • 77955492857 scopus 로고    scopus 로고
    • Bristol-Myers Squibb Sanofi-aventis, Bridgewater, NJ, Sanofi-aventis
    • Plavix (clopidogrel bisulfate) [package insert] 2010, Bristol-Myers Squibb Sanofi-aventis, Bridgewater, NJ, Sanofi-aventis.
    • (2010) Plavix (clopidogrel bisulfate) [package insert]
  • 16
    • 54449095374 scopus 로고    scopus 로고
    • Clopidogrel use and bleeding after coronary artery bypass graft surgery
    • Kim J.H., Newby L.K., Clare R.M., et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 2008, 156:886-892.
    • (2008) Am Heart J , vol.156 , pp. 886-892
    • Kim, J.H.1    Newby, L.K.2    Clare, R.M.3
  • 17
    • 34249053105 scopus 로고    scopus 로고
    • The disposition of prasugrel, a novel thienopyridine, in humans
    • Farid N.A., Smith R.L., Gillespie T.A., et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007, 35:1096-1104.
    • (2007) Drug Metab Dispos , vol.35 , pp. 1096-1104
    • Farid, N.A.1    Smith, R.L.2    Gillespie, T.A.3
  • 18
    • 33645105318 scopus 로고    scopus 로고
    • Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
    • Rehmel J.L., Eckstein J.A., Farid N.A., et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006, 34:600-607.
    • (2006) Drug Metab Dispos , vol.34 , pp. 600-607
    • Rehmel, J.L.1    Eckstein, J.A.2    Farid, N.A.3
  • 19
  • 20
    • 68649094164 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease
    • Small D.S., Farid N.A., Li Y.G., et al. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease. J Clin Pharm Ther 2009, 34:575-583.
    • (2009) J Clin Pharm Ther , vol.34 , pp. 575-583
    • Small, D.S.1    Farid, N.A.2    Li, Y.G.3
  • 21
    • 34447271701 scopus 로고    scopus 로고
    • Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status
    • Weerakkody G.J., Jakubowski J.A., Brandt J.T., et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 2007, 100:331-336.
    • (2007) Am J Cardiol , vol.100 , pp. 331-336
    • Weerakkody, G.J.1    Jakubowski, J.A.2    Brandt, J.T.3
  • 22
    • 36348977461 scopus 로고    scopus 로고
    • Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
    • Payne C.D., Li Y.G., Small D.S., et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007, 50:555-562.
    • (2007) J Cardiovasc Pharmacol , vol.50 , pp. 555-562
    • Payne, C.D.1    Li, Y.G.2    Small, D.S.3
  • 23
    • 79952355781 scopus 로고    scopus 로고
    • Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability
    • Ancrenaz V., Daali Y., Fontana P., et al. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 2010, 11:667-677.
    • (2010) Curr Drug Metab , vol.11 , pp. 667-677
    • Ancrenaz, V.1    Daali, Y.2    Fontana, P.3
  • 24
    • 69249219296 scopus 로고    scopus 로고
    • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
    • Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-857.
    • (2009) JAMA , vol.302 , pp. 849-857
    • Shuldiner, A.R.1    O'Connell, J.R.2    Bliden, K.P.3
  • 25
    • 67649645191 scopus 로고    scopus 로고
    • Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    • Varenhorst C., James S., Erlinge D., et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009, 30:1744-1752.
    • (2009) Eur Heart J , vol.30 , pp. 1744-1752
    • Varenhorst, C.1    James, S.2    Erlinge, D.3
  • 26
    • 77958567291 scopus 로고    scopus 로고
    • Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data
    • Sorich M.J., Vitry A., Ward M.B., et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010, 8:1678-1684.
    • (2010) J Thromb Haemost , vol.8 , pp. 1678-1684
    • Sorich, M.J.1    Vitry, A.2    Ward, M.B.3
  • 27
    • 37349103200 scopus 로고    scopus 로고
    • Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
    • Farid N.A., Payne C.D., Ernest C.S., et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol 2008, 48:53-59.
    • (2008) J Clin Pharmacol , vol.48 , pp. 53-59
    • Farid, N.A.1    Payne, C.D.2    Ernest, C.S.3
  • 28
    • 57149084688 scopus 로고    scopus 로고
    • Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
    • Farid N.A., Small D.S., Payne C.D., et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008, 28:1483-1494.
    • (2008) Pharmacotherapy , vol.28 , pp. 1483-1494
    • Farid, N.A.1    Small, D.S.2    Payne, C.D.3
  • 29
    • 34247256797 scopus 로고    scopus 로고
    • Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
    • Farid N.A., Payne C.D., Small D.S., et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007, 81:735-741.
    • (2007) Clin Pharmacol Ther , vol.81 , pp. 735-741
    • Farid, N.A.1    Payne, C.D.2    Small, D.S.3
  • 30
    • 67650844202 scopus 로고    scopus 로고
    • Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects
    • Farid N.A., Jakubowski J.A., Payne C.D., et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin 2009, 25:1821-1829.
    • (2009) Curr Med Res Opin , vol.25 , pp. 1821-1829
    • Farid, N.A.1    Jakubowski, J.A.2    Payne, C.D.3
  • 31
    • 40749094082 scopus 로고    scopus 로고
    • Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    • Small D.S., Farid N.A., Payne C.D., et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008, 48:475-484.
    • (2008) J Clin Pharmacol , vol.48 , pp. 475-484
    • Small, D.S.1    Farid, N.A.2    Payne, C.D.3
  • 32
    • 50249184573 scopus 로고    scopus 로고
    • Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    • Small D.S., Farid N.A., Li Y.G., et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin 2008, 24:2251-2257.
    • (2008) Curr Med Res Opin , vol.24 , pp. 2251-2257
    • Small, D.S.1    Farid, N.A.2    Li, Y.G.3
  • 34
    • 77953896604 scopus 로고    scopus 로고
    • Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis
    • Hulot J.S., Collet J.P., Silvain J., et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010, 56:134-143.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 134-143
    • Hulot, J.S.1    Collet, J.P.2    Silvain, J.3
  • 35
    • 36348943475 scopus 로고    scopus 로고
    • Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
    • Brandt J.T., Close S.L., Iturria S.J., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007, 5:2429-2436.
    • (2007) J Thromb Haemost , vol.5 , pp. 2429-2436
    • Brandt, J.T.1    Close, S.L.2    Iturria, S.J.3
  • 36
    • 77649332028 scopus 로고    scopus 로고
    • Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial
    • Small D.S., Payne C.D., Kothare P., et al. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther 2010, 32:365-379.
    • (2010) Clin Ther , vol.32 , pp. 365-379
    • Small, D.S.1    Payne, C.D.2    Kothare, P.3
  • 37
    • 76949099975 scopus 로고    scopus 로고
    • The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
    • Small D.S., Kothare P., Yuen E., et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol 2010, 66:127-135.
    • (2010) Eur J Clin Pharmacol , vol.66 , pp. 127-135
    • Small, D.S.1    Kothare, P.2    Yuen, E.3
  • 38
    • 77955618350 scopus 로고    scopus 로고
    • Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial
    • Ge J., Zhu J., Hong B.K., et al. Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. Curr Med Res Opin 2010, 26:2077-2085.
    • (2010) Curr Med Res Opin , vol.26 , pp. 2077-2085
    • Ge, J.1    Zhu, J.2    Hong, B.K.3
  • 39
    • 61549124132 scopus 로고    scopus 로고
    • Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
    • Ho P.M., Maddox T.M., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301:937-944.
    • (2009) JAMA , vol.301 , pp. 937-944
    • Ho, P.M.1    Maddox, T.M.2    Wang, L.3
  • 40
    • 78149487926 scopus 로고    scopus 로고
    • Clopidogrel with or without omeprazole in coronary artery disease
    • COGENT Investigators
    • Bhatt D.L., Cryer B.L., Contant C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363:1909-1917. COGENT Investigators.
    • (2010) N Engl J Med , vol.363 , pp. 1909-1917
    • Bhatt, D.L.1    Cryer, B.L.2    Contant, C.F.3
  • 41
    • 84856618024 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration, February 3, 2009, Accessed January 5, 2011
    • Cardiovascular and Renal Drug Advisory Committee Briefing Document U.S. Food and Drug Administration, February 3, 2009, Accessed January 5, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm129219.pdf.
    • Cardiovascular and Renal Drug Advisory Committee Briefing Document
  • 42
    • 37349111065 scopus 로고    scopus 로고
    • Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
    • PRINCIPLE-TIMI 44 Investigators
    • Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007, 116:2923-2932. PRINCIPLE-TIMI 44 Investigators.
    • (2007) Circulation , vol.116 , pp. 2923-2932
    • Wiviott, S.D.1    Trenk, D.2    Frelinger, A.L.3
  • 43
    • 21644448736 scopus 로고    scopus 로고
    • Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial
    • Wiviott S.D., Antman E.M., Winters K.J., et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005, 111:3366-3373.
    • (2005) Circulation , vol.111 , pp. 3366-3373
    • Wiviott, S.D.1    Antman, E.M.2    Winters, K.J.3
  • 45
    • 54149097794 scopus 로고    scopus 로고
    • Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
    • Murphy S.A., Antman E.M., Wiviott S.D., et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008, 29:2473-2479.
    • (2008) Eur Heart J , vol.29 , pp. 2473-2479
    • Murphy, S.A.1    Antman, E.M.2    Wiviott, S.D.3
  • 46
    • 60649112469 scopus 로고    scopus 로고
    • Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
    • Montalescot G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009, 373:723-731.
    • (2009) Lancet , vol.373 , pp. 723-731
    • Montalescot, G.1    Wiviott, S.D.2    Braunwald, E.3
  • 47
    • 55949103494 scopus 로고    scopus 로고
    • Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38
    • Wiviott S.D., Braunwald E., Angiolillo D.J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118:1626-1636.
    • (2008) Circulation , vol.118 , pp. 1626-1636
    • Wiviott, S.D.1    Braunwald, E.2    Angiolillo, D.J.3
  • 48
    • 68949183521 scopus 로고    scopus 로고
    • Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy
    • Pride Y.B., Wiviott S.D., Buros J.L., et al. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am Heart J 2009, 158:e21-e26.
    • (2009) Am Heart J , vol.158
    • Pride, Y.B.1    Wiviott, S.D.2    Buros, J.L.3
  • 49
    • 42149119040 scopus 로고    scopus 로고
    • Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
    • TRITON-TIMI 38 Investigators
    • Wiviott S.D., Braunwald E., McCabe C.H., et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008, 371:1353-1363. TRITON-TIMI 38 Investigators.
    • (2008) Lancet , vol.371 , pp. 1353-1363
    • Wiviott, S.D.1    Braunwald, E.2    McCabe, C.H.3
  • 50
    • 43749117048 scopus 로고    scopus 로고
    • Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis
    • Antman E.M., Wiviott S.D., Murphy S.A., et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008, 51:2028-2033.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 2028-2033
    • Antman, E.M.1    Wiviott, S.D.2    Murphy, S.A.3
  • 51
    • 74249088972 scopus 로고    scopus 로고
    • Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study
    • Montalescot G., Sideris G., Cohen R., et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010, 103:213-223.
    • (2010) Thromb Haemost , vol.103 , pp. 213-223
    • Montalescot, G.1    Sideris, G.2    Cohen, R.3
  • 52
    • 77956681628 scopus 로고    scopus 로고
    • Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study
    • SWAP Investigators
    • Angiolillo D.J., Saucedo J.F., Deraad R., et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010, 56:1017-1023. SWAP Investigators.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 1017-1023
    • Angiolillo, D.J.1    Saucedo, J.F.2    Deraad, R.3
  • 53
    • 0025851456 scopus 로고
    • Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial
    • Bovill E.G., Terrin M.L., Stump D.C., et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991, 115:256-265.
    • (1991) Ann Intern Med , vol.115 , pp. 256-265
    • Bovill, E.G.1    Terrin, M.L.2    Stump, D.C.3
  • 54
    • 79957668478 scopus 로고    scopus 로고
    • FDA Advisory Committee Docket, Accessed December 29, 2010
    • FDA Advisory Committee Docket, Accessed December 29, 2010. http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-01-FDA.pdf.
  • 55
    • 36548998846 scopus 로고    scopus 로고
    • Universal definition of myocardial infarction
    • Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction
    • Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation 2007, 116:2634-2653. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction.
    • (2007) Circulation , vol.116 , pp. 2634-2653
    • Thygesen, K.1    Alpert, J.S.2    White, H.D.3
  • 56
    • 67649158245 scopus 로고    scopus 로고
    • Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction
    • Morrow D.A., Wiviott S.D., White H.D., et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009, 119:2758-2764.
    • (2009) Circulation , vol.119 , pp. 2758-2764
    • Morrow, D.A.1    Wiviott, S.D.2    White, H.D.3
  • 57
    • 68249144596 scopus 로고    scopus 로고
    • The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis
    • O'Donoghue M., Antman E.M., Braunwald E., et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 2009, 54:678-685.
    • (2009) J Am Coll Cardiol , vol.54 , pp. 678-685
    • O'Donoghue, M.1    Antman, E.M.2    Braunwald, E.3
  • 58
    • 77950249728 scopus 로고    scopus 로고
    • Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients
    • Dauerman H.L., Bhatt D.L., Gretler D.D., et al. Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J 2010, 159:508-517.
    • (2010) Am Heart J , vol.159 , pp. 508-517
    • Dauerman, H.L.1    Bhatt, D.L.2    Gretler, D.D.3
  • 59
    • 74549154500 scopus 로고    scopus 로고
    • Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38
    • Mahoney E.M., Wang K., Arnold S.V., et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010, 121:71-79.
    • (2010) Circulation , vol.121 , pp. 71-79
    • Mahoney, E.M.1    Wang, K.2    Arnold, S.V.3
  • 60
    • 71849087338 scopus 로고    scopus 로고
    • Platelet inhibition with cangrelor in patients undergoing PCI
    • Harrington R.A., Stone G.W., McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009, 361:2318-2329.
    • (2009) N Engl J Med , vol.361 , pp. 2318-2329
    • Harrington, R.A.1    Stone, G.W.2    McNulty, S.3
  • 61
    • 71849119604 scopus 로고    scopus 로고
    • Intravenous platelet blockade with cangrelor during PCI
    • CHAMPION PLATFORM Investigators
    • Bhatt D.L., Lincoff A.M., Gibson C.M., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009, 361:2330-2341. CHAMPION PLATFORM Investigators.
    • (2009) N Engl J Med , vol.361 , pp. 2330-2341
    • Bhatt, D.L.1    Lincoff, A.M.2    Gibson, C.M.3
  • 63
    • 70649090353 scopus 로고    scopus 로고
    • Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot
    • Berger J.S., Roe M.T., Gibson C.M., et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 2009, 158:998-1004.
    • (2009) Am Heart J , vol.158 , pp. 998-1004
    • Berger, J.S.1    Roe, M.T.2    Gibson, C.M.3
  • 64
    • 73149118496 scopus 로고    scopus 로고
    • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients
    • Gurbel P.A., Bliden K.P., Antonino M.J., et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost 2010, 8:43-53.
    • (2010) J Thromb Haemost , vol.8 , pp. 43-53
    • Gurbel, P.A.1    Bliden, K.P.2    Antonino, M.J.3
  • 66
    • 77955677366 scopus 로고    scopus 로고
    • Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)
    • Leonardi S., Rao S.V., Harrington R.A., et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 2010, 160:65-72.
    • (2010) Am Heart J , vol.160 , pp. 65-72
    • Leonardi, S.1    Rao, S.V.2    Harrington, R.A.3
  • 67
    • 79957630981 scopus 로고    scopus 로고
    • Rao S, for the INNOVATE PCI investigators. A randomized, doubleblind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions. Presented at European Society of Cardiology Congress. Stockholm, Sweden, Aug
    • Rao S, for the INNOVATE PCI investigators. A randomized, doubleblind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions. Presented at European Society of Cardiology 2010 Congress. Stockholm, Sweden, August 30, 2010.
    • (2010)
  • 68
    • 70149101223 scopus 로고    scopus 로고
    • Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    • Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
    • (2009) N Engl J Med , vol.361 , pp. 1045-1057
    • Wallentin, L.1    Becker, R.C.2    Budaj, A.3
  • 69
    • 77955690680 scopus 로고    scopus 로고
    • Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial
    • TRILOGY ACS Steering Committee
    • Chin C.T., Roe M.T., Fox K.A., et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010, 160:16-22. TRILOGY ACS Steering Committee.
    • (2010) Am Heart J , vol.160 , pp. 16-22
    • Chin, C.T.1    Roe, M.T.2    Fox, K.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.